Cassava Sciences reports Q3 EPS (58c) vs. (61c) last year

“We look forward to the release of top-line results from RETHINK-ALZ, our first Phase 3 trial for simulfilam, by the end of 2024,” said Rick Barry, President and Chief Executive Officer. “This will represent the culmination of three-plus years of concerted effort by our clinical team, principal investigators, patients and their caregivers.”